Literature DB >> 12385082

Mechanisms and treatments of SSRI-induced sexual dysfunction.

Norman L Keltner1, Kelly M McAfee, Carey L Taylor.   

Abstract

SSRI-induced sexual dysfunction affects 30% to 50% or more of individuals who take these drugs for depression. Biochemical mechanisms suggested as causative include increased serotonin, particularly affecting 5HT2 and 5HT3 receptors; decreased dopamine; blockade of cholinergic and alpha-1 adrenergic receptors; inhibition of nitric oxide synthetase; and elevation of prolactin levels. Five approaches to treatment include conservative approaches such as wait and see, decrease dosage, and drug holidays. More aggressive strategy for treating SSRI-induced sexual dysfunction are changing antidepressants and augmentation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12385082

Source DB:  PubMed          Journal:  Perspect Psychiatr Care        ISSN: 0031-5990            Impact factor:   2.186


  18 in total

1.  How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications.

Authors:  Dean Elbe; Robert Savage
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2010-02

2.  Relationship between SSRI-induced sexual dysfunction and central serotonergic activity based on the loudness dependence of auditory evoked potentials.

Authors:  Young-Min Park
Journal:  Psychopharmacology (Berl)       Date:  2013-09-05       Impact factor: 4.530

3.  Management strategies for SSRI-induced sexual dysfunction.

Authors:  Sakina J Rizvi; Sidney H Kennedy
Journal:  J Psychiatry Neurosci       Date:  2013-09       Impact factor: 6.186

4.  Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial.

Authors:  Amirhossein Modabbernia; Hamid Sohrabi; Abbas-Ali Nasehi; Firoozeh Raisi; Sepideh Saroukhani; Amirhossein Jamshidi; Mina Tabrizi; Mandana Ashrafi; Shahin Akhondzadeh
Journal:  Psychopharmacology (Berl)       Date:  2012-05-03       Impact factor: 4.530

5.  Sexual Functioning in Adolescents With Major Depressive Disorder.

Authors:  Emira Deumic; Brandon D Butcher; Anita D Clayton; Lilian N Dindo; Trudy L Burns; Chadi A Calarge
Journal:  J Clin Psychiatry       Date:  2016-07       Impact factor: 4.384

Review 6.  Late-stage clinical development in lower urogenital targets: sexual dysfunction.

Authors:  Usman Azam
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

7.  Milnacipran: a unique antidepressant?

Authors:  Siegfried Kasper; Gerald Pail
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

8.  Antidepressant-associated sexual dysfunction: impact, effects, and treatment.

Authors:  Agnes Higgins; Michael Nash; Aileen M Lynch
Journal:  Drug Healthc Patient Saf       Date:  2010-09-09

Review 9.  Tolerability and safety of fluvoxamine and other antidepressants.

Authors:  H G M Westenberg; C Sandner
Journal:  Int J Clin Pract       Date:  2006-04       Impact factor: 2.503

10.  Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial.

Authors:  Vahid Farnia; Mehdi Shirzadifar; Jalal Shakeri; Mansour Rezaei; Hafez Bajoghli; Edith Holsboer-Trachsler; Serge Brand
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-09       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.